{"id":113589,"date":"2026-08-10T11:11:14","date_gmt":"2026-08-10T11:11:14","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/113589\/"},"modified":"2026-08-10T11:11:14","modified_gmt":"2026-08-10T11:11:14","slug":"chemometec-enters-collaboration-agreement-with-roche-diagnostics","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/113589\/","title":{"rendered":"ChemoMetec enters collaboration agreement with Roche Diagnostics"},"content":{"rendered":"<p>ANNOUNCEMENT NO. 311<\/p>\n<p>After entering a Letter of Intent with Roche Diagnostics in February 2026, aiming to pursue a collaboration with the goal of creating synergies between the parties\u2019 solutions in the field of bioprocess monitoring, ChemoMetec and Roche Diagnostics have today entered a collaboration agreement.<\/p>\n<p>The agreement covers the development of a connection kit between the Roche-owned Cedex\u00ae Bio Analyzer and the ChemoMetec-owned Xcytomatic\u00ae 30 (XM30) cell counting analyzer, as well as aspects of the subsequent commercialization of the connectivity solution.<\/p>\n<p>Get the latest news<br \/>\n                <br class=\"br-line\"\/><br \/>\n                delivered to your inbox<\/p>\n<p>Sign up for The Manila Times newsletters<\/p>\n<p>            By signing up with an email address, I acknowledge that I have read and agree to the <a href=\"https:\/\/www.manilatimes.net\/terms-of-service\" title=\"Terms of Service\" rel=\"nofollow noopener\" target=\"_blank\">Terms of Service<\/a> and <a href=\"https:\/\/www.manilatimes.net\/privacy-policy\" title=\"Privacy Policy\" rel=\"nofollow noopener\" target=\"_blank\">Privacy Policy<\/a>.<\/p>\n<p>Roche will be responsible for the design of the connection kit and for the verification and validation activities. The connection kit is intended to result in a connectivity solution on hard- and software level, establishing a flawless integration and connection between the ChemoMetec XM30 and the Roche Cedex\u00ae Bio Analyzer.\u00a0\u00a0<\/p>\n<p>The two parties commit to a joint go-to-market strategy to actively co-promote the combined solution to current and prospective customers, but each party will remain the sole seller of its respective instrument and analyzers.<\/p>\n<p>Additional Information<\/p>\n<p>Martin Helbo Behrens, CEO<\/p>\n<p>Tel.: (+45) 81 10 06 80<\/p>\n<p>About ChemoMetec A\/S<\/p>\n<p>ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec\u2019s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec\u2019s customers include some of the world\u2019s leading pharmaceutical companies.<\/p>\n<p>ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For further information, go to <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=res0mdDlclE-w6iGuPi2eiPxqtCeYvzgsvJ4_Qa5QRZUOLbv-5TJcTgzkamXgKH9qQiBCp6PTWZQXoOxen3-2B2yZu0EDHLONyXkj3zq6OY=\" rel=\"nofollow noopener\" target=\"_blank\">www.chemometec.com<\/a>.<\/p>\n<p>Attachment<\/p>\n<p><a target=\"_blank\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=CtUyCM2u45MZi8JehmuU8fQI7xWqJPDI7uLMxG9BcvHKghtB6y5W-EpjTNJSfDVIf8LZS2Wz9oO0ZqC_FDTAgOgaFfpfX-r38V8-Q9v-8kb4cwAbZwAg-Mp_DRAFBcO9Ai9rcrP9GhJy3puv8pK_gj-HVwTrhGHMoBYmvtdmeQZY-PSevGEpAqYowA_nh-dDx2Hu9Pvc41IswkQvwJWGMw==\" rel=\"nofollow noopener\">Announcement 311 &#8211; Roche Collaboration Agreement<\/a><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/08\/Chemometec-A-S.png\"\/><\/p>\n","protected":false},"excerpt":{"rendered":"ANNOUNCEMENT NO. 311 After entering a Letter of Intent with Roche Diagnostics in February 2026, aiming to pursue&hellip;\n","protected":false},"author":2,"featured_media":113590,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[12132,55299,2059,1176,27536,134,3737],"class_list":["post-113589","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-agreement","tag-chemometec","tag-collaboration","tag-diagnostics","tag-enters","tag-roche","tag-with"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117070914097270151","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/113589","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=113589"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/113589\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/113590"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=113589"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=113589"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=113589"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}